MediGene

News MediGene

• MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases

  MediGene AG continues clinical development of its drug candidate RhuDex® by initiating a clinical formulation study. The trial objective is to develop an optimized oral formulation of the active substance suitable for the treatment of chronic diseases. The results of this formulation study are expec more

• MediGene Receives Authorization for the Clinical Formulation Study of RhuDex

  MediGene AG announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) granted the authorization of the planned clinical formulation study of RhuDex®, a drug candidate being developed for the treatment of rheumatoid arthritis. The objective of the RapidFACTTM trial more

• MediGene and Pharmanova Sign Agreement for the Commercialization of Veregen in Southeastern Europe

  MediGene AG  has signed an exclusive license and supply agreement with Pharmanova d.o.o. for the supply and commercialization of Veregen® ointment in Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania, for the treatment of genital warts. MediGene is entitled to suc more

Market studies MediGene

• Portugal Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: A year has passed since the EU/IMF/ECB’s rescue package was approved, and the obligations that form part of the economic adjustment programme have had, and will continue to have, a central role in redefining Portugal’s pharmaceutical and healthcare market. Cost-cutting measures are continu more

• Portugal Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: A year has passed since the EU/IMF/ECB’s rescue package was approved, and the obligations that form part of the economic adjustment programme have had, and will continue to have, a central role in redefining Portugal’s pharmaceutical and healthcare market. Cost-cutting measures are continu more

Websites MediGene